Congress should build on the value-based insurance design (VBID) elements included in the Inflation Reduction Act to further alleviate the burden of health care costs on Americans, said A. Mark Fendrick, MD, co–editor in chief of The American Journal of Managed Care® and director of the V-BID Center at the University of Michigan.
Congress should build on the value-based insurance design (VBID) elements included in the Inflation Reduction Act (IRA) to further alleviate the burden of health care costs on Americans, said A. Mark Fendrick, MD, co–editor in chief of The American Journal of Managed Care® and director of the V-BID Center at the University of Michigan.
Transcript
What additional VBID elements would you like to see the government adopt?
Well, while we were very pleased to see the insulin out-of-pocket cap of $35
implemented for Medicare, we fell just a few votes short of having this as a national policy for all plans. So it is our hope that Congress will revisit the commercial plan out-of-pocket cap and then we could see insulin out-of-pocket cost no longer be such a burden for everyone who is insured.
Another area that we’re working on is to expand the Internal Revenue Service list of chronic disease services that could be covered on a predeductible basis. We were happy to see the codification of predeductible coverage for insulin in the IRA. We would like to see this to include many other highly valuable evidence-based services used to manage and prevent the complications of chronic conditions that are not included in the 14 services that already have this allowable predeductible coverage.
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More
Empowering Teams Begins With Human Connection: Missy Hopson, PhD
April 16th 2025Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.
Read More